NEWTOWN, Pa.--(BUSINESS WIRE)--BioClinica®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, is quickly becoming the eClinical provider of choice for European pharmaceutical, medical device, biotechnology and contract research organizations (CROs). BioClinica’s combination of nimble programing, scalability, ease of use, and high value are winning the attention of European companies tired of outdated, slow-moving, cumbersome eClinical systems.
As clinical trials become increasingly global in nature, there is a growing call for software solutions and services that get trials up and running faster with less cost. BioClinica is answering this need with a full range of industry-leading eClinical products, solutions, and services that help launch and manage studies with a minimum of effort at a cost far below those typically associated with such high levels of functionality.
European-based contracts are not new for BioClinica and have historically accounted for a significant portion of sales. Clients range from global pharmaceutical and medical device companies to large and small CROs. BioClinica’s recent European projects include the deployment of multiple eClinical solutions such as Optimizer, OnPoint CTMS, Trident IWR, and Express EDC, as well as world-class Data Management services.
With European headquarters in Leiden, The Netherlands, as well as offices in Lyon, France, BioClinica not only has the technology to support European customers, but also the dedicated resources on the continent to support the adoption and deployment of our technology. BioClinica is also adding skilled positions to support its growing business expectations.
“European trial sponsors are really seeing the difference compared to the ‘one-size-fits-all’ providers,” said Peter Benton, BioClinica’s president of eClinical Solutions. “BioClinica specializes in clinical trial solutions, and our products are built to easily conform to each individual study rather than forcing the study to fit into a mold. Our various solutions, such as OnPoint CTMS, Trident IWR, and Express EDC integrate with each other to help get studies running quickly and efficiently.”
BioClinica’s products are recognized for the “Office Smart” capabilities which harness the power of SharePoint and the Microsoft Office Suite to provide study project managers a comprehensive, real-time view into trial performance. This allows pharmaceutical, biotech, and medical device manufacturers to leverage their existing investments in Microsoft Office to better interact with their trial data, reduce the training timeline, and get studies up and running faster.
BioClinica will demonstrate its eClinical solutions at DIA EuroMeeting March 26 – 28, 2012 in Copenhagen, Denmark at Booth 138. Conference attendees are encouraged to contact Martijn Princen at 49.151.2232.1864 or Martijn.Princen@bioclinica.com to learn ways to streamline their trials and more efficiently manage their data.
About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com
Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.